{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:42:30Z","timestamp":1776343350191,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.14283\/jpad.2024.106","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T06:30:19Z","timestamp":1717482619000},"page":"1260-1269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8737-5256","authenticated-orcid":false,"given":"Yasuo","family":"Toda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.K.","family":"Muralidharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Budd","family":"Haeberlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.106_bib1","unstructured":"Organization WH. Risk reduction of cognitive decline and dementia: WHO guidelines. 2019"},{"issue":"4","key":"10.14283\/jpad.2024.106_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/geront\/gnr067","article-title":"Japan: super-aging society preparing for the future","volume":"51","author":"Muramatsu","year":"2011","journal-title":"Gerontologist"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators GBDD","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2024.106_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CEOR.S146788","article-title":"Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan","volume":"10","author":"Montgomery","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"11","key":"10.14283\/jpad.2024.106_bib6","doi-asserted-by":"crossref","first-page":"e0206508","DOI":"10.1371\/journal.pone.0206508","article-title":"The estimated cost of dementia in Japan, the most aged society in the world","volume":"13","author":"Sado","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13696998.2021.1877149","article-title":"Humanistic burden among caregivers of patients with Alzheimer's disease or dementia in Japan: a large-scale cross-sectional survey","volume":"24","author":"Ohno","year":"2021","journal-title":"J Med Econ"},{"issue":"4","key":"10.14283\/jpad.2024.106_bib8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40120-023-00492-7","article-title":"Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation","volume":"12","author":"Igarashi","year":"2023","journal-title":"Neurol Ther"},{"key":"10.14283\/jpad.2024.106_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathmechdis-012418-012936","article-title":"Molecular Pathogenesis of the Tauopathies","volume":"14","author":"Gotz","year":"2019","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.14283\/jpad.2024.106_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"18","key":"10.14283\/jpad.2024.106_bib12","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.14283\/jpad.2024.106_bib13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"7618","key":"10.14283\/jpad.2024.106_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2024.106_bib16","series-title":"ADUHELM (aducanumab) [prescribing information]","year":"2021"},{"issue":"12","key":"10.14283\/jpad.2024.106_bib17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41594-020-0505-6","article-title":"Kinetic fingerprints differentiate the mechanisms of action of anti-Abeta antibodies","volume":"27","author":"Linse","year":"2020","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"10.14283\/jpad.2024.106_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.14283\/jpad.2024.106_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14283\/jpad.2023.6","article-title":"Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab","volume":"10","author":"Mallinckrodt","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.106_bib22","series-title":"National Research Council (US) Panel on Race E, and Health in Later Life. Ethnic Differences in Dementia and Alzheimer's Disease. In: Anderson NB BR, Cohen B, editors, ed. Critical Perspectives on Racial and Ethnic Differences in Health in Late Life","year":"2004"},{"issue":"8","key":"10.14283\/jpad.2024.106_bib23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jalz.2018.03.009","article-title":"Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials","volume":"14","author":"Iwatsubo","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.14283\/jpad.2024.106_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1399-0004.1986.tb01901.x","article-title":"A racial difference in apolipoprotein E allele frequencies between the Japanese and Caucasian populations","volume":"30","author":"Eto","year":"1986","journal-title":"Clin Genet"},{"issue":"4","key":"10.14283\/jpad.2024.106_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/alzrt86","article-title":"Globalization of Alzheimer's disease clinical trials","volume":"3","author":"Cummings","year":"2011","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-015-0122-5","article-title":"Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials","volume":"7","author":"Grill","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.14283\/jpad.2024.106_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.14283\/jpad.2024.106_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","article-title":"Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial","volume":"30","author":"Sevigny","year":"2016","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.14283\/jpad.2024.106_bib31","series-title":"Amyvid (Florbetapir F 18 Injection) [prescribing information]","year":"2012"},{"key":"10.14283\/jpad.2024.106_bib32","article-title":"VIZAMYL (flutemetamol F 18 injection) [prescribing information]","year":"2013","journal-title":"Cardinal Health"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.106_bib34","doi-asserted-by":"crossref","first-page":"790654","DOI":"10.1155\/2013\/790654","article-title":"Body fat and body-mass index among a multiethnic sample of college-age men and women","volume":"2013","author":"Carpenter","year":"2013","journal-title":"J Obes"},{"issue":"5","key":"10.14283\/jpad.2024.106_bib35","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1079\/BJN20061745","article-title":"Differences in the relationship between BMI and percentage body fat between Japanese and Australian-Caucasian young men","volume":"95","author":"Kagawa","year":"2006","journal-title":"Br J Nutr"},{"issue":"7","key":"10.14283\/jpad.2024.106_bib36","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2337\/dc06-0057","article-title":"Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study","volume":"29","author":"Shai","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.14283\/jpad.2024.106_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.14283\/jpad.2024.106_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.14283\/jpad.2024.106_bib39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.14283\/jpad.2024.106_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:14:41Z","timestamp":1737339281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724006551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2274580724006551"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.106","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}